AI Takes Center Stage at SCOPE 2026: New Oncology Trial Systems Aim to End 'Referral Black Holes' and Slash Timelines
At the SCOPE 2026 summit, Massive Bio and ConcertAI unveiled competing AI-driven platforms designed to tackle chronic inefficiencies in oncology clinical trials, from patient enrollment to study design, promising faster, more reliable pathways for new cancer therapies.